Leading Pharmaceutical Company Selects Kinaxis to Cure Supply Chain Headaches
May 21 2024 - 7:00AM
Business Wire
Kinaxis to drive supply chain efficiencies for
Servier’s targeted portfolio of lifesaving drugs
Kinaxis® Inc. (TSX: KXS), a global leader in end-to-end supply
chain orchestration, today announced that Servier, a global
independent pharmaceutical group, has selected Kinaxis to help
revolutionize its supply chain planning capabilities with a view to
accelerating time to market for its portfolio of life-saving
drugs.
One of the world’s preeminent pharmaceutical companies, Servier
has nearly 22,000 employees and a presence in 150 countries, with
medicines targeting cancers, diabetes, as well as
immune-inflammatory, neuropsychiatric, cardiovascular, and venous
diseases. The company’s unique status as a laboratory governed by a
non-profit foundation sees it invest upwards of 20% of its revenue
each year from brand-name medicines into research and development,
a strategy that has enabled it to accelerate research to discover
new treatments faster for the benefits of patients.
As part of the deployment, Kinaxis will enable Servier to plan
more effectively and gain critical end-to-end visibility of its
overall supply chain; a vital requirement as competing
jurisdictional regulations, demand variability, and increased
global disruptions play havoc with the pharmaceutical industry’s
mission to deliver high-quality products to customers at the lowest
cost and with the shortest lead time.
“One of Servier’s principal ambitions is to be a resilient,
growing, and sustainable company that’s focused on a few areas
where we can make the greatest impact globally for patients,”
said Xavier Morelon, head of supply chain at Servier. “To do
so, we know we should rely on best-in-class partners like Kinaxis
which are so critical to helping us become more agile and ensuring
our supply chain can enable us to hit this lofty objective.”
“From making sure patients have the right medications when they
need them to keeping up with regulations, expiry dates, and patent
cliffs, no industry can compare to life sciences when it comes to
complexity,” said Fabienne Cetre, regional vice president,
Central Europe at Kinaxis. “We’re thrilled to be working with
Servier and are confident our deep industry expertise will enable
everyone from their C-suite to their planners and analysts to see
more clearly through these challenges so that they can focus on
what they do best – delivering products to help people live longer
and healthier lives.”
With the addition of France’s second largest pharmaceutical
company to its growing customer base, Kinaxis continues to cement
its leadership within the life sciences industry, which provides
the brand-name and generic medicines that countless patients rely
on.
Kinaxis’ AI-powered software allows companies to orchestrate
their supply chain network end to end, from strategic planning to
last-mile delivery. Kinaxis’ technology helps companies that supply
the agricultural industry with 40% of the world’s tractors, that
keep more than 110 billion teeth clean each year, and that ensures
more than 35 million pets are fed nutritious meals each year.
To learn more about Kinaxis and its supply chain management
solutions, please visit Kinaxis.com.
About Kinaxis
Kinaxis is a global leader in modern supply chain orchestration.
We serve supply chains and the people who manage them in service of
humanity. Our software is trusted by renowned global brands to
provide the agility and predictability needed to navigate today’s
volatility and disruption. We combine our patented concurrency
technique with a human-centered approach to AI to empower
businesses of all sizes to manage their end-to-end supply chain
network, from multi-year strategic planning through
down-to-the-second execution and last-mile delivery. For more news
and information, please visit kinaxis.com or follow us on
LinkedIn.
About Servier
Founded to serve health, Servier is a global pharmaceutical
group governed by a Foundation that aspires to have a meaningful
social impact, both for patients and for a sustainable world. With
its unique governance model, it can fully serve its vocation with a
long-term vision: being committed to therapeutic progress to serve
patient needs. The 21,900 employees of the Group are committed to
this shared vocation, a source of inspiration every day.
As a world leader in cardiology, Servier’s ambition is to become
a focused and innovative player in oncology by targeting hard-to
treat cancers. That is why the Group allocates over 70% of its
R&D budget to developing targeted and innovative therapies in
oncology. Neuroscience and immuno-inflammatory diseases are the
future growth drivers.
In these areas, Servier is focused on a limited number of
diseases in which accurate patient profiling makes it possible to
offer a targeted therapeutic response through precision medicine.
To promote access to quality care for all at a lower cost, the
Group also offers a range of quality generic drugs covering most
pathologies, relying on strong brands in France, Eastern Europe,
Brazil and Nigeria.
In all these areas, the Group includes the patient voice at each
stage of the life cycle of a medicine. Headquartered in France,
Servier relies on a strong geographical footprint in over 150
countries and achieved a revenue of €5.3 billion in 2023.
More information on the new Group website: servier.com
Follow us on social media: LinkedIn, Facebook, Twitter,
Instagram
Source: Kinaxis
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240521977758/en/
Media Relations Jaime Cook | Kinaxis jcook@kinaxis.com
289-552-4640 Investor Relations Rick Wadsworth | Kinaxis
rwadsworth@kinaxis.com 613-907-7613 Servier:
presse@servier.com
Kinaxis (TSX:KXS)
Historical Stock Chart
From May 2024 to Jun 2024
Kinaxis (TSX:KXS)
Historical Stock Chart
From Jun 2023 to Jun 2024